Over the past few years, a new class of medications has transformed the treatment of obesity. Drugs like Ozempic, Wegovy and Mounjaro work primarily by reducing appetite, helping people eat less and feel full sooner. Their ...
Mar 14, 2026
0
10
Diet‑related diseases such as type 2 diabetes, obesity and hypertension, particularly those affecting children, remain stubbornly high. Can public policies like those that have been successful with tobacco control help shape ...
Mar 13, 2026
0
8
As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing ...
Mar 13, 2026
0
16
New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London has found that excessive smartphone use is closely associated with disordered eating, including uncontrolled eating ...
Mar 13, 2026
0
7
Many teens dealing with weight issues are turning to AI models to help them create meal plans with the aim of losing weight. But a new study shows that the resulting plans may not always adequately cover necessary nutrients ...
Mar 12, 2026
0
13
A new clinic-ready web-based risk prediction tool called PsyMetRiC is now available to forecast the risk of young people with psychosis developing cardiometabolic disorders such as obesity, metabolic syndrome and diabetes.
Mar 11, 2026
0
8
A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It's a simple premise: What if something as small as a digital nudge could put someone on the path to healthier ...
Mar 11, 2026
0
7
Researchers at the University of California, Irvine Joe C. Wen School of Population & Public Health have identified how the hormone asprosin influences long-term weight change among postmenopausal women in the United States. ...
Mar 11, 2026
0
8
Patients without diabetes who switched GLP-1 receptor agonist (GLP-1RA) drugs for overweight or obesity were more likely to stick with their treatment longer than those who didn't switch, according to a new study by UT Southwestern ...
Mar 10, 2026
0
13
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published ...
Mar 10, 2026
0
69
